pramipexole
Adjunctive therapy • Brands: Mirapex
Last reviewed: 2025-12-30
General information
- Class: Adjunctive therapy
- Common US brands: Mirapex
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Non-ergoline dopamine agonist (D2/D3-preferring) indicated for Parkinson’s disease and moderate-to-severe primary restless legs syndrome; largely renally eliminated as unchanged drug with clinically important somnolence, impulse- control, hallucination/psychosis, and RLS augmentation considerations.
Metabolism & Half‑life
- Metabolism: Negligible metabolism (<10%); not CYP-mediated (label).
- Half‑life: Single-dose range 8–12 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Pramipexole dihydrochloride tablets prescribing information — DailyMed (2025)
- Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2025)
- The Management of Restless Legs Syndrome: An Updated Algorithm — Mayo Clinic Proceedings (2021)
- Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood — Sleep Medicine (2011)